Abstract
Scleroderma is a severe systemic disorder affecting 240 per million of population, characterized by fibrosis of the skin and internal organs, by autoimmune phenomena, and by vascular injury (for review, see1). Scleroderma patients form a heterogeneous group with a very wide spectrum of disease severity. In the most mildly affected individuals, Raynaud’s phenomenon and barely noticeable skin thickening may be the only manifestations of the disease. At the opposite end of the disease spectrum are patients with total skin encasement and life-threatening pulmonary, cardiac, or renal complications.2
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557-567
Black CM, Stephens CO (1993) Scleroderma-systemic sclerosis. In: Maddison PJ, Isenberg D, Woo P, Glass DN (eds) Oxford Textbook of Rheumatology. Oxford University Press, Oxford, pp 771-789
Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wolheim F (1988) Scleroderma; classification, subsets, and pathogenesis. J Rheumatol 15:202-205
Steen VD, Medsger TA Jr (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940-944
Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15:778-784
Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203
Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617-625
Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF (1988) Clinical associations of anti-centromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 31:378-385
Catagio LJ, Bernstein RM, Black CM, Hughes GRV, Maddison PJ (1983) Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 42:23-27
Kuwana MJ, Kaburaki J, Mimori T, Tojo T, Homma M (1993) Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 91:1399-1404
Okano Y, Steen VD, Medsger TA Jr (1993) Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 119:1005-1013
Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, Burns A (2007) Denton CP Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100:485-494
Reimer G, Rose KM, Scheer U, Tan EM (1987) Autoantibody to RNA polymerase I in scleroderma sera. J Clin Invest 79:65-72
Kahaleh MB (2004) Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 16:718-722
Kahaleh MB, LeRoy EC (1979) Endothelial injury in scleroderma. J Exp Med 149:1326-1335
Harrison NK, Myers AR, Corrin B, Soosay G, Dewar A, Black CM, Du Bois RM (1991) Turner-Warwick M.Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 144(3 Pt 1):706-713
Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98(3):785-792
Echberg MR, Nilsson IK, Linell F (1981) Significance of increased factor VIII in early glomerulonephritis. Ann Intern Med 94:482-484
Boneu B, Bierme R, Fournier A, Ponkonner G (1977) Factor VIII complex, fetal growth retardation and toxaemia. Lancet 1:263
Nusinow SR, Federici AB, Zimmerman TS, Curd JG (1984) Increased Von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum 27:1405-1409
Drenk F, Deicher HR (1988) Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. J Rheumatol 15:468-474
Gordon JL, Pottinger BE, Woo P, Rosenbaum J, Black CM (1987) Plasma von Willebrand factor in connective tissue disease. Ann Rheum Dis 46:491-492
Kahaleh MB, Osborn I, LeRoy EC (1981) Increased factor VIII von Willebrand factor antigen and von Willebrand factor activity in scleroderma and Raynaud’s phenomenon. Ann Int Med 94:482-484
Yamane K, Miyauchi T, Suzuki N, Miyauchi T, Yanagisawa M, Goto K, Masaki T (1991) Elevated levels of plasma endothelin-1 in systemic sclerosis. Arthritis Rheum 34:243-244
Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM (1994) Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction. J Rheumatol 21:1838-1844
Springer TA (1990) Adhesion molecules of the immune system. Nature 346:425-433
Pigott R, Dillon LP, Hemingway IH, Gearing AJH (1992) Soluble forms of E-selectin, ICAM-1, and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584-589
Gearing JH, Newman W (1993) Circulating adhesion molecules in disease. Immunology Today 14:506-512
Bevilaqua MP, Stengelin S, Gimbrone MA Jr, Seed B (1989) Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243:1160-1165
Blann AD, Herrick A, Jayson MIV (1995) Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis, and systemic sclerosis. Br J Rheumatol 34:814-819
Claman HN, Giorno RC, Seibold JR (1991) Endothelial and fibroblast activation in scleroderma. Arthritis Rheum 34:1495
Gruschwitz MS, Hornstein OP, Von Den Driesch P (1995) Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in-situ expression and with disease activity. Arthritis Rheum 38:184-189
Gruschwitz MS, Vieth G (1997) Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon gamma and tumour necrosis factor alpha in the early disease stage. Arthritis Rheum 40:540-550
Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ (1996) VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localised scleroderma. Br J Dermatol 135:678-686
Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GC (1993) Circulating ICAM-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68:88-92
Shi-Wen X, Panesar M, Vancheeswaran R, Mason J, Haskard DO, Black CM, Olsen IO, Abraham DJ (1994) Expression and shedding of ICAM-1 and LFA-3 by scleroderma and normal fibroblasts. Arthritis Rheum 37:1689-1697
Solberg S, Peltonen J, Uitto J, Jiminez S (1992) Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 35:290-298
Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ, Black CM (1998) Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 91(8):561-566
Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Haznedaroglu IC, Cobankara V, Pay S, Calguneri M (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48:2256-2261
Pober JS, Bevilacqua MP, Mendrick DL, Lapieree LA, Fiers W, Gimbrone MA (1986) Two distinct monokines interleukin-1 and tumour necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 136:1680-1687
Hakkert BC, Kuijpers TW, Leeuwenberg JF, Van Mourik JA, Roos D (1991) Neutrophil and monocyte adherence to and migration across monolayers of cytokine activated endothelial cells: the contribution of CD 18, ELAM-1, and VLA-4. Blood 78:2721-2726
Picker LJ, Warnock RA, Burns AR, Doerschuk CM, Berg EL, Butcher EC (1991) The neutrophil selectin LECAM-1 presents carbohydrate ligands to the vascular selectins ELAM-1 and GMP-140. Cell 66:921-933
Shimuzu Y, Newman W, Gopal TV, Horgan KJ, Graber N, Beall LD, van Seventer GA, Shaw S (1991) Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditions. J Cell Biol 113:1203-1212
Ghilardi G, Biondi ML, Turri O, Guagnellini E, Scorza R (2004) Ser128Arg gene polymorphism for E-selectin and severity of atherosclerotic arterial disease. J Cardiovasc Surg (Torino) 45:143-147
Rauchhaus M, Gross M, Schulz S et al (2002) The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty. Int J Cardiol 83:249-257
Boehme MWJ, Schmitt WH, Youinou P, Stremmel WR, Gross WL (1996) Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener’s granulomatosis and other systemic vasculitides. Am J Med 101:387-394
Dittman WA, Majerus PW (1990) Structure and function of thrombomodulin: a natural anticoagulant. Blood 75:329-336
Ishi H, Majerus PW (1985) Thrombomodulin is present in human serum and urine. J Clin Invest 76:2178-2184
Chaouat A, Weitzenblum E, Higenbottam T (1996) The role of thrombosis in severe pulmonary hypertension. Eur Resp J 9:356-363
Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S (1990) Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 82:841-847
Cacoub P, Karmochkine M, Dorent R, Nataf P, Piette JC, Godeu P, Gandjbakhch I, Boffa MC (1996) Plasma levels of thrombomodulin in pulmonary hypertension. Am J Med 101:160-164
Welsh CH, Hassell KL, Badesh DB, Kressin DC, Marlar RA (1996) Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110:710-717
Stratton RJ, Pompon L, Coghlan JG, Pearson JD, Black CM (2000) Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension. Ann Rheum Dis 59:132-134
Ishii H, Uchiyama H, Kazama M (1991) Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65:618-623
Malek AM, Jackman R, Rosenberg RD, Izumo S (1994) Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Clin Res 74:852-860
Shreeniwas R, Ogawa S, Cozzolino F, Torcia G, Braunstein N, Butura C, Brett J, Lieberman HB, Furie MB, Joseph-Silverstein J (1991) Macrovascular and microvascular endothelium during long term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J Cell Physiol 146:8-17
Shreeniwas R, Ogawa S, Cozzolino F, Torcia G, Braunstein N, Butura C et al (1991) Macrovascular and microvascular endothelium during long term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J Cell Physiol 146:8-17
Cohen S, Johnson R, Hurd E (1983) Cytotoxicity of sera from patients with scleroderma. Effects on human endothelial cells and fibroblasts in culture. Arthritis Rheum 26:170-178
Blake DR, Winyard P, Scott DGI, Brailsford S, Blann A, Lunec J (1991) Endothelial cell cytotoxicity in inflammatory vascular diseases-the possible role of oxidised lipoproteins. Ann Rheum Dis 44:176-182
Blann AD, Illingworth K, Jayson MI (1993) Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud’s phenomenon. J Rheumatol 20(8):1325-1330
Lindqvist RJ, Osterland CK (1971) Human antibodies to vascular endothelium. Clin Exp Immunol 9:753-760
Cervera R, Khamashta MA, Hughes GRV (1993) Antibodies to endothelial cells and vascular damage. CRC Press, Boca Raton, FL, pp 83-184
Del Papa N, Conforti G, Gambini D, La Rosa L, Tincani A, D’Cruz D, Khamashta M, Hughes GRV, Balastriere G (1994) and Meroni PL Characterisation of the endothelial surface proteins recognised by anti endothelial antibodies in primary and secondary autoimmune vasculitis. Clin Immunol Immunopathol 70:211-216
Del Papa N, Gambini D, Meroni PL (1994) Anti-endothelial cell antibodies in autoimmune disease. Clin Rev Allergy 12:275-286
Hashemi S, Smith CD, Izaguirre CA (1987) Anti-endothelial cell antibodies: detection and characterisation using a cellular enzyme-linked immunosorbent assay. J Lab Clin Med 109:434-440
Holt CM, Lindsey N, Moult J, Malia RG, Greaves M, Hume A, Rowell N, Hughes P (1989) Antibody-dependent cellular cytotoxicity of vascular endothelium: characterisation and pathogenic associations in systemic sclerosis. Clin Exp Immunol 78:359-365
Penning CA, Cunningham J, French MAH, Harrison G, Rowell NR, Hughes P (1984) Antibody dependent cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol 57:548-556
Rosenbaum JR, Pottinger BE, Woo P, Black CM, Byron MA, Pearson JD (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72:450-456
Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cells from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium derived cytokines. J Clin Invest 97:111-119
Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43(11):2550-2562
Van Der Zee JM, Seigert CEH, De Vreede TA, Daha MR, Breedveld FC (1991) Characterisation of anti-endothelial cell antibodies in systemic lupus erythematosus. Clin exp Immunol 84:238-244
Tuffanelli DL, Winkelmann RF (1961) Systemic scleroderma : a clinical study of 727 cases. Arch Dermatol 84:359-371
Wigley FM (1993) Raynaud’s phenomenon. Curr Opin Rheumatol 5:773-784
D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis. A study of fifty eight autopsy cases and fifty eight matched controls. Am J Med 46:428-440
Young RH, Mark GJ (1978) Pulmonary vascular changes in scleroderma. Am J Med 64:998-1004
Rubin LJ (1993) Primary pulmonary hypertension. Chest 104:236-250
Salerni R, Rodnan GP, Leon DF (1984) Shaver JA Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 86:394-399
Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr (1986) Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 29:515-524
Al-Sabbagh MR, Steen VD, Zee BC, Nalesnik M, Trostle DC, Bedetti CD, Medsger TA Jr (1989) Pulmonary artery histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 16:1038-1042
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesh D, Groves B, Tapson VF, Barge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn SD, Shortino D, Crow JW (1996) A comparison of continuous intravenous epoprostinol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296-301
Rodnan GP, Benedek TG (1962) An historical account of the study of progressive systemic sclerosis(diffuse scleroderma). Ann Intern Med 57:305-319
Shapiro AP, Medsger TA. Renal Involvment in Systemic Sclerosis. In Diseases of the Kidney.4th ed. Schreiner R and Gottschalk C, eds. USA: Little, Brown; 1988:2273-2283
Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC (1974) The relationship of hypertension and renal failure in scleroderma to structural and functional abnormalities of the renal cortical circulation. Medicine 53:1-46
Trostle DC, Bedetti CD, Steen VD, Al-Sabbagh MR, Zee B, Medsger TA Jr (1988) Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 31:393-400
Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH, Steen VD, Osial T Jr, Tolchin SR (1983) Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Medicine 62:335-352
Medsger TA, Masi AT, Rodnan GP, Benedek TG, Robinson H (1971) Survival with systemic sclerosis. Ann Int Med 75:369-376
Steen VD, Costantino JP, Shapiro AP, Medsger TA (1990) Outcome of renal crisis in systemic sclerosis:relation to the availability of angiotensin converting enzyme inhibitors. Ann Int Med 113:352-357
Beckett VL, Donadio JV, Brennan LA, Comm DL, Osmundson PJ, Chao EY, Holley KE (1985) Use of captopril as early therapy for renal scleroderma: a prospective study. Mayo Clin Proc 60:763-771
Palmer RM, Ashton DS, Moncada S (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666
DeWitt DL, Day JS, Sonnenburg WK, Smith WL (1983) Concentrations of prostaglandin endoperoxide synthase and prostaglandin I2 synthase in the endothelium and smooth muscle of bovine aorta. J Clin Invest 72:1882-1888
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by endothelial cells. Nature 332:411-415
Takagi K, Kawaguchi Y, Hara M, Sugiura T, Harigai M, Kamatani N (2003) Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol 134:538-544
Yamamoto T, Katayama I, Nishioka K (1998) Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 25(2):314-317
Romero LI, Zhang DN, Cooke JP, Ho HK, Avalos E, Herrera R, Herron GS (2000) Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vasc Med 5(3):147-158
Cotton SA, Herrick AL, Jayson MI, Freemont AJ (1999) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 189:273-278
Belch JJ, McLaren M, Anderson J, Lowe GD, Sturrock RD, Capell HA, Forbes CD (1985) Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome. Prostaglandins Leukot Med 17:1-9
Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241-250
Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159(6):1925-1932
Klimiuk PS, Taylor L, Baker RD, Jayson MI (1988) Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 47(7):542-545
Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM (1990) Deficiency of calcitonin gene-related peptide in Raynaud’s phenomenon. Lancet 336(8730):1530-1533
Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA (2000) Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278(4):H1075-H1083
Flavahan NA, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener CM, Spence RJ, Wigley FM (2000) Increased α2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 43:1886-1890
Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2005) Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 24(2):111-116
Danese C, Parlapiano C, Zavattaro E, Di Prima M, Campana E, Rota C, Tonnarini G, Di Siena G, Borgia MC (1997) ET-1 plasma levels during cold stress test in sclerodermic patients. Angiology 48(11):965-968
Tabata H, Yamakage A, Yamazaki S (1997) Cutaneous localization of endothelin-1 in patients with systemic sclerosis: immunoelectron microscopic study. Int J Dermatol 36(4):272-275
Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ (2004) Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 15(6):2707-2719
Hettema ME, Zhang D, Bootsma H, Kallenberg CG (2007) Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis. Ann Rheum Dis 66(10):1398-1399
Riccardi MT, Chialà A, Lannone F, Grattagliano V, Covelli M, Lapadula G (2007) Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan). Reumatismo 59(2):135-139
Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, Weber C, Macdonald PS (2000) Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 102(4):411-418
Denton CP, Humbert M, Rubin L, Black CM (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65(10):1336-1340
Finch MB, Dawson J, Johnston GD (1986) The peripheral vascular effects of nifedipine in Raynaud’s syndrome associated with scleroderma: a double blind crossover study. Clin Rheumatol 5:493-498
de la Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ (1994) Long term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 37:1528-1533
Kyle MV, Belcher G, Hazleman BL (1992) Placebo-controlled study showing therapeutic benefit of Iloprost in the treatment of Raynaud’s phenomenon. J Rheumatol 19:1403-1406
Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, Kirby JD (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 298(6673):561-564
Sinzinger H, Zidek T, Fitscha P, O’Grady J, Wagner O, Kaliman J (1987) Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivo. Prostaglandins 33(6):915-918
Weber AA, Zucker TP, Hasse A, Bönisch D, Wittpoth M, Schrör K (1998) Antimitogenic effects of vasodilatory prostaglandins in coronary artery smooth muscle cells. Basic Res Cardiol 93(3):54-57
Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH (2008) Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol 214(2):434-441
Rybalkin S, Yan C, Bornfeldt K, Beavo J (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291
Hayakawa I, Shirasaki F, Hirano T, Oishi N, Hasegawa M, Sato S, Takehara K (2006) Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int 26(3):270-273
Gore J, Silver R (2005) Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 64(9):1387
Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N (2007) Simonneau G Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34(12):2417-2422
Tantini B, Manes A, Fiumana E et al (2005) Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100:131-138
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag London
About this chapter
Cite this chapter
Nuttall, A., Derrett-Smith, E., Stratton, R. (2009). Advances in Vascular Medicine. In: Abraham, D., Clive, H., Dashwood, M., Coghlan, G. (eds) Advances in Vascular Medicine. Springer, London. https://doi.org/10.1007/978-1-84882-637-3_19
Download citation
DOI: https://doi.org/10.1007/978-1-84882-637-3_19
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84882-636-6
Online ISBN: 978-1-84882-637-3
eBook Packages: MedicineMedicine (R0)